AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35498440 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (10 mg/day)
Number of subjects: 48
Study 33118535 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of cancer (FHC)
Number of subjects: 3455
Study 33118535 — intervention group
Group type: COMPARATOR
Intervention: No family history of cancer (NFHC)
Number of subjects: 3455
Study 35377708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 750
Study 35377708 — intervention group
Group type: COMPARATOR
Intervention: No maintenance (observation)
Number of subjects: 750
Study 32160826 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light
Number of subjects: 112
Study 32160826 — intervention group
Group type: COMPARATOR
Intervention: Dim white light
Number of subjects: 112
Study 32160826 — intervention group
Group type: COMPARATOR
Intervention: Red light
Number of subjects: 112
Study 32160826 — intervention group
Group type: COMPARATOR
Intervention: Blue light
Number of subjects: 112
Study 36293902 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 97
Study 36293902 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (controls)
Number of subjects: 97
Study 34872283 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Number of subjects: 90
Study 34872283 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Number of subjects: 90
Study 34872283 — intervention group
Group type: COMPARATOR
Intervention: Normal saline combined with sevoflurane
Number of subjects: 90
Study 34215501 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus tailored exercise training (foam dressing, short-stretch bandage, stretching, resistive, and aerobic exercise sessions, 3 days/week for 12 weeks)
Number of subjects: 24
Study 34215501 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (foam dressing, short-stretch bandage)
Number of subjects: 24
Study 34215501 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus tailored exercise training
Number of subjects: 24
Study 34215501 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 24
Study 33849113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis combined with levocarnitine
Number of subjects: 75
Study 35757205 — intervention group
Group type: EXPERIMENTAL
Intervention: Climbing (n = 26)
Number of subjects: 66
Study 35757205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (n = 19)
Number of subjects: 66
Study 35757205 — intervention group
Group type: COMPARATOR
Intervention: Social contact control (n = 21)
Number of subjects: 66
Study 35757205 — intervention group
Group type: EXPERIMENTAL
Intervention: Climbing and Nordic walking
Number of subjects: 66
Study 32198520 — intervention group
Group type: COMPARATOR
Intervention: Brief telephone advice (BA)
Number of subjects: 153
Study 32198520 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages (TM)
Number of subjects: 153
Study 32198520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy (NRT)
Number of subjects: 153
Study 32198520 — intervention group
Group type: EXPERIMENTAL
Intervention: TM + NRT
Number of subjects: 153
Study 32198520 — intervention group
Group type: COMPARATOR
Intervention: BA
Number of subjects: 153
Study 32198520 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 153
Study 32198520 — intervention group
Group type: EXPERIMENTAL
Intervention: TM
Number of subjects: 153
Study 34304487 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt-Daroff training combined with otolith reposition instrument
Number of subjects: 110
Study 34304487 — intervention group
Group type: COMPARATOR
Intervention: Otolith reposition and health education (Control)
Number of subjects: 110
Study 36154908 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CBD Isolate
Number of subjects: 150
Study 36154908 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CBD Broad Spectrum
Number of subjects: 150
Study 36154908 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 150
Study 33707768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization applied to quantitative traits
Number of subjects: 0
Study 33707768 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic investigations of biomarkers
Number of subjects: 0
Study 33707768 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein drug targets
Number of subjects: 0
Study 33707768 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug targets
Number of subjects: 0
Study 33707768 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic epidemiological studies
Number of subjects: 0
Study 32347209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-healing training
Number of subjects: 34
Study 35722465 — intervention group
Group type: EXPERIMENTAL
Intervention: rCCK96‐104PE38 targeted drug
Number of subjects: 80
Study 35722465 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin
Number of subjects: 80
Study 34533039 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione infusion (2500 mg/25 mL over 10 minutes, followed by the same doses at 24, 48, and 72 hours)
Number of subjects: 100
Study 34533039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34243733 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective caries removal
Number of subjects: 623
Study 34243733 — intervention group
Group type: COMPARATOR
Intervention: Complete caries removal
Number of subjects: 623
Study 32487243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude (HVLA) lumbar manipulation
Number of subjects: 24
Study 32487243 — intervention group
Group type: COMPARATOR
Intervention: Simulated manipulation (Control)
Number of subjects: 24
Study 35531796 — intervention group
Group type: EXPERIMENTAL
Intervention: PN-HPT® (4 ml intradermally)
Number of subjects: 20
Study 35531796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid (2 ml subdermally)
Number of subjects: 20
Study 35531796 — intervention group
Group type: COMPARATOR
Intervention: Saline (4 ml intradermally)
Number of subjects: 20
Study 33244605 — intervention group
Group type: EXPERIMENTAL
Intervention: Food crop diversity
Number of subjects: 880
Study 33244605 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to markets
Number of subjects: 880
Study 33244605 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's salaried employment
Number of subjects: 880
Study 32909076 — intervention group
Group type: EXPERIMENTAL
Intervention: ebselen (600 mg bd)
Number of subjects: 68
Study 32909076 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 35686561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg once daily for 16 weeks
Number of subjects: 135
Study 35686561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 35686561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 135
Study 33453418 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (GLP-1 analogue)
Number of subjects: 37
Study 33453418 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 32414331 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKKO (supportive care intervention including patient navigator, oncological knowledge database, specialized oncological counseling)
Number of subjects: 0
Study 32414331 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKKO (supportive care intervention)
Number of subjects: 0
Study 32414331 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 33608976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for adolescents + brief cognitive intervention to decrease self-criticism
Number of subjects: 40
Study 32866634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional vitamin D3
Number of subjects: 56
Study 32866634 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using eosin
Number of subjects: 56
Study 32866634 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 35381840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IV group)
Number of subjects: 0
Study 35381840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine instillation (IP group)
Number of subjects: 0
Study 35381840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33740316 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) on
Number of subjects: 16
Study 33740316 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) off
Number of subjects: 16
Study 33740316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pain threshold
Number of subjects: 16
Study 33740316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold hyperalgesia
Number of subjects: 16
Study 33200626 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg elemental calcium daily until 20 weeks' gestation, then 1.5 g until delivery)
Number of subjects: 630
Study 33200626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 33200626 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 630
Study 35829749 — intervention group
Group type: EXPERIMENTAL
Intervention: 166Ho TARE
Number of subjects: 6
Study 35829749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural holmium-sensitive MRI
Number of subjects: 6
Study 35829749 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in MRI
Number of subjects: 6
Study 35829749 — intervention group
Group type: EXPERIMENTAL
Intervention: Last fraction of treatment
Number of subjects: 6
Study 32356515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 4.5 g, titrated to 6 or 9 g
Number of subjects: 246
Study 32356515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 6 g, increased to 9 g
Number of subjects: 246
Study 32356515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 32356515 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 246
Study 32356515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) and Modafinil
Number of subjects: 246
Study 33280218 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic insertion of feeding tube gastrostomy (FTG)
Number of subjects: 34
Study 33280218 — intervention group
Group type: COMPARATOR
Intervention: Open surgery for feeding tube gastrostomy (FTG)
Number of subjects: 34
Study 33667135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC) for 12 months
Number of subjects: 88
Study 33667135 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 88
Study 33684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1139
Study 33684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1139
Study 33684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (dose escalation)
Number of subjects: 1139
Study 33684552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study 33684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Cohort (including patients from OCTAVE Induction 1 and 2, OCTAVE Sustain, and OCTAVE Open)
Number of subjects: 1139
Study 36361460 — intervention group
Group type: EXPERIMENTAL
Intervention: High Machiavellianism
Number of subjects: 869
Study 36361460 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological capital (for female university students)
Number of subjects: 869
Study 36361460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation effect (for male university students)
Number of subjects: 869
Study 35012812 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg
Number of subjects: 100
Study 35012812 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine 8 μg
Number of subjects: 100
Study 32434847 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine (9.0 × 10^5 PfSPZ)
Number of subjects: 39
Study 32434847 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine (4.5 × 10^5 PfSPZ)
Number of subjects: 39
Study 32434847 — intervention group
Group type: COMPARATOR
Intervention: PfSPZ Vaccine (4.5 × 10^5 PfSPZ)
Number of subjects: 39
Study 32434847 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 39
Study 32434847 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine (both doses)
Number of subjects: 39
Study 36102803 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS based on wrist‐ankle acupuncture
Number of subjects: 31
Study 36102803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 34407542 — intervention group
Group type: EXPERIMENTAL
Intervention: asciminib 40 mg twice daily
Number of subjects: 233
Study 34407542 — intervention group
Group type: COMPARATOR
Intervention: bosutinib 500 mg once daily
Number of subjects: 233
Study 34407542 — intervention group
Group type: EXPERIMENTAL
Intervention: asciminib
Number of subjects: 233
Study 32034814 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg) from Fangming Pharmaceutical Group (Test, T)
Number of subjects: 48
Study 32034814 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg) from NORVASC® (Reference, R)
Number of subjects: 48
Study 35717662 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific movement program (TSM program) for 4 weeks (60 minutes per session, total of 15 sessions)
Number of subjects: 22
Study 35717662 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation program (total of 12 sessions)
Number of subjects: 22
Study 32222806 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group (36 patients)
Number of subjects: 98
Study 32222806 — intervention group
Group type: COMPARATOR
Intervention: Non-statin group (62 patients)
Number of subjects: 98
Study 32222806 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 98
Study 32222806 — intervention group
Group type: COMPARATOR
Intervention: Non-statin group
Number of subjects: 98
Study 32222806 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 98
Study 36348372 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative home-based strength training protocol
Number of subjects: 248
Study 36348372 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy during hospitalization
Number of subjects: 248
Study 34154590 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 10 mg
Number of subjects: 397
Study 34154590 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 20 mg
Number of subjects: 397
Study 34154590 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix 40 mg
Number of subjects: 397
Study 34154590 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin 3.75 mg
Number of subjects: 397
Study 34154590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 32384434 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding treatment (two weeks at predefined acupuncture points: Shenshu (BL23), Sanyinjiao (SP6), Guanyuan (RN4), Ganshu (BL18), Zusanli (ST36), Pishu (BL20))
Number of subjects: 70
Study 32384434 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam tablet (0.4 mg, 1 tablet, 3 times a day)
Number of subjects: 70
Study 32384434 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) and proton magnetic resonance spectroscopy (1H-MRS) scans
Number of subjects: 70
Study 35031868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L-PEG/Asc
Number of subjects: 202
Study 35031868 — intervention group
Group type: COMPARATOR
Intervention: 2 L-PEG/Asc
Number of subjects: 202
Study 34579620 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal consultation (VC) + HSWAP
Number of subjects: 0
Study 34579620 — intervention group
Group type: COMPARATOR
Intervention: Verbal consultation (VC) only (pre-crossover control)
Number of subjects: 0
Study 34579620 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal consultation (VC) + HSWAP (post-crossover control)
Number of subjects: 0
Study 33706003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion XL 300 mg/day
Number of subjects: 0
Study 33706003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32559029 — intervention group
Group type: COMPARATOR
Intervention: MTA only
Number of subjects: 18
Study 32559029 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA + EMP
Number of subjects: 18
Study 32559029 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA + rhPDGF
Number of subjects: 18
Study 36001100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib/XR
Number of subjects: 62010
Study 36001100 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 62010
Study 36001100 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 62010
Study 33038505 — intervention group
Group type: EXPERIMENTAL
Intervention: New waiver program
Number of subjects: 0
Study 33038505 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing Medicaid expansion program)
Number of subjects: 0
Study 32132655 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Number of subjects: 779
Study 32132655 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 779
Study 33183068 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA-zeolite-clinoptilolite
Number of subjects: 0
Study 33183068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35248019 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary vein/subclavian vein (AxV/SCV) approach
Number of subjects: 248
Study 35248019 — intervention group
Group type: COMPARATOR
Intervention: Internal jugular vein (IJV) approach
Number of subjects: 248
Study 34654402 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy comprising 25 Gy in 5 fractions with concomitant (150 mg/m2/day, 5 days) and adjuvant temozolomide
Number of subjects: 270
Study 34654402 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy comprising 40 Gy in 15 fractions with concomitant (75 mg/m2/day, every day from first to last day of radiation) and adjuvant temozolomide
Number of subjects: 270
Study 34654402 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy comprising 25 Gy in 5 fractions with concomitant and adjuvant temozolomide
Number of subjects: 270
Study 34654402 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy comprising 40 Gy in 15 fractions with concomitant and adjuvant temozolomide
Number of subjects: 270
Study 35387783 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT plus ultrasound guided intra‐articular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine
Number of subjects: 199
Study 35387783 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT plus ultrasound guided intra‐articular hip injection of 5 mL 1% lidocaine
Number of subjects: 199
Study 35387783 — intervention group
Group type: COMPARATOR
Intervention: BCT (best current treatment)
Number of subjects: 199
Study 33119332 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive supervisor training (SST)
Number of subjects: 250
Study 35640099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-Silent-Oral (OSO) condition
Number of subjects: 21
Study 35640099 — intervention group
Group type: COMPARATOR
Intervention: Silent-Oral (SO) condition
Number of subjects: 21
Study 36357273 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 65
Study 36357273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 33608260 — intervention group
Group type: COMPARATOR
Intervention: EXER intervention
Number of subjects: 0
Study 33608260 — intervention group
Group type: COMPARATOR
Intervention: CBT intervention
Number of subjects: 0
Study 33608260 — intervention group
Group type: COMPARATOR
Intervention: EXER1CBT intervention
Number of subjects: 0
Study 33109331 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical fixation using Conformité Européenne‐marked headless compression screws.
Number of subjects: 439
Study 33109331 — intervention group
Group type: COMPARATOR
Intervention: Below-elbow cast immobilisation for 6-10 weeks and urgent fixation of confirmed non-union.
Number of subjects: 439
Study 35986465 — intervention group
Group type: EXPERIMENTAL
Intervention: Phos‐Flur gel (study group)
Number of subjects: 56
Study 35986465 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (control group)
Number of subjects: 56
Study 33162800 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 60
Study 33162800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 60
Study 33162800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Volume-Guaranteed Ventilation (PCV-VG)
Number of subjects: 60
Study 34332606 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident ROA at knee level
Number of subjects: 1295
Study 34332606 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident ROA at patient level
Number of subjects: 1295
Study 34332606 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1295
Study 34332606 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 1295
Study 34332606 — intervention group
Group type: EXPERIMENTAL
Intervention: Female
Number of subjects: 1295
Study 34332606 — intervention group
Group type: EXPERIMENTAL
Intervention: Less ROM
Number of subjects: 1295
Study 34332606 — intervention group
Group type: EXPERIMENTAL
Intervention: KL grade 1 at baseline
Number of subjects: 1295
Study 33144594 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking together with self-selected turns and speed changes
Number of subjects: 2